- Effective at 5 pm ET October 27, 2022 - CHARLESTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences…
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented…
WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its…
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that…
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA,…
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused…
Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to AdherenceMORRISVILLE, N.C., Oct.…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…